Tanezumab, an emergent NGF-neutralizing antibody, has shown effectiveness against arthritis pain and other symptoms, but its clinical viability is questionable due to marked adverse reactions at high doses and limited effectiveness at lower doses (47, 48). This evidence concerns the gene NGF and Arthritis.